Annual SGA
$11.36 M
+$1.68 M+17.32%
December 1, 2023
Summary
- As of February 21, 2025, RNTX annual SGA is $11.36 million, with the most recent change of +$1.68 million (+17.32%) on December 1, 2023.
- During the last 3 years, RNTX annual SGA has risen by +$2.03 million (+21.73%).
Performance
RNTX SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly SGA
$2.35 M
-$2.95 M-55.66%
September 1, 2024
Summary
- As of February 21, 2025, RNTX quarterly SGA is $2.35 million, with the most recent change of -$2.95 million (-55.66%) on September 1, 2024.
- Over the past year, RNTX quarterly SGA has dropped by -$1.39 million (-37.23%).
Performance
RNTX Quarterly SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
TTM SGA
-$1.20 B
-$29.24 M-2.50%
September 1, 2024
Summary
- As of February 21, 2025, RNTX TTM SGA is -$1.20 billion, with the most recent change of -$29.24 million (-2.50%) on September 1, 2024.
- Over the past year, RNTX TTM SGA has dropped by -$1.21 billion (-9381.25%).
Performance
RNTX TTM SGA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Selling, General & Administrative Expenses Formula
SGA = Total Operating Expenses - Cost of Goods Sold - Research & Development
RNTX Selling, General & Administrative Expenses Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +17.3% | -37.2% | -9381.3% |
| 3 y3 years | +21.7% | +7.8% | -10000.0% |
| 5 y5 years | -15.6% | -31.7% | -10000.0% |
RNTX Selling, General & Administrative Expenses Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | -15.5% | -55.9% | -19.4% | +27.3% | at low |
| 5 y | 5-year | -7.6% | -17.8% | -55.9% | -19.4% | +60.3% | at low |
| alltime | all time | -15.6% | -55.5% | -55.9% | -42.3% | +948.7% | at low |
Rein Therapeutics Selling, General & Administrative Expenses History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | $2.35 M(-55.7%) | $16.72 M(+2.4%) |
| Jun 2024 | - | $5.30 M(+41.6%) | $16.32 M(+26.4%) |
| Mar 2024 | - | $3.74 M(-29.8%) | $12.92 M(+13.8%) |
| Dec 2023 | $11.36 M(+17.3%) | $5.33 M(+172.6%) | $11.36 M(+36.4%) |
| Sep 2023 | - | $1.96 M(+3.3%) | $8.33 M(-3.3%) |
| Jun 2023 | - | $1.89 M(-13.1%) | $8.62 M(-7.7%) |
| Mar 2023 | - | $2.18 M(-5.3%) | $9.33 M(-3.6%) |
| Dec 2022 | $9.68 M(+0.9%) | $2.30 M(+2.6%) | $9.68 M(+0.5%) |
| Sep 2022 | - | $2.24 M(-14.0%) | $9.63 M(-2.7%) |
| Jun 2022 | - | $2.61 M(+3.2%) | $9.90 M(+4.8%) |
| Mar 2022 | - | $2.53 M(+12.1%) | $9.45 M(-1.5%) |
| Dec 2021 | $9.60 M(+2.9%) | $2.25 M(-10.3%) | $9.60 M(-0.1%) |
| Sep 2021 | - | $2.51 M(+16.6%) | $9.61 M(+1.8%) |
| Jun 2021 | - | $2.16 M(-19.3%) | $9.44 M(+2.7%) |
| Mar 2021 | - | $2.67 M(+17.9%) | $9.20 M(-1.4%) |
| Dec 2020 | $9.33 M | $2.27 M(-3.3%) | $9.33 M(-3.8%) |
| Sep 2020 | - | $2.34 M(+22.6%) | $9.70 M(-10.2%) |
| Jun 2020 | - | $1.91 M(-31.9%) | $10.80 M(-9.7%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2020 | - | $2.81 M(+6.4%) | $11.96 M(-2.7%) |
| Dec 2019 | $12.29 M(-8.6%) | $2.64 M(-23.3%) | $12.29 M(-3.0%) |
| Sep 2019 | - | $3.44 M(+11.9%) | $12.68 M(+2.1%) |
| Jun 2019 | - | $3.08 M(-2.0%) | $12.41 M(-9.2%) |
| Mar 2019 | - | $3.14 M(+3.9%) | $13.68 M(+1.7%) |
| Dec 2018 | $13.45 M(+53.4%) | $3.02 M(-4.9%) | $13.45 M(+2.2%) |
| Sep 2018 | - | $3.18 M(-26.8%) | $13.16 M(+4.6%) |
| Jun 2018 | - | $4.34 M(+48.7%) | $12.59 M(+25.4%) |
| Mar 2018 | - | $2.92 M(+6.8%) | $10.04 M(+14.5%) |
| Dec 2017 | $8.77 M(+11.1%) | $2.73 M(+5.0%) | $8.77 M(+18.6%) |
| Sep 2017 | - | $2.60 M(+45.2%) | $7.39 M(+15.2%) |
| Jun 2017 | - | $1.79 M(+8.7%) | $6.42 M(-20.7%) |
| Mar 2017 | - | $1.65 M(+21.5%) | $8.09 M(+2.5%) |
| Dec 2016 | $7.89 M(+56.0%) | $1.36 M(-16.7%) | $7.89 M(+20.7%) |
| Sep 2016 | - | $1.63 M(-53.0%) | $6.54 M(+33.1%) |
| Jun 2016 | - | $3.46 M(+139.6%) | $4.91 M(+239.6%) |
| Mar 2016 | - | $1.45 M | $1.45 M |
| Dec 2015 | $5.06 M | - | - |
FAQ
- What is Rein Therapeutics annual SGA?
- What is the all time high annual SGA for Rein Therapeutics?
- What is Rein Therapeutics annual SGA year-on-year change?
- What is Rein Therapeutics quarterly SGA?
- What is the all time high quarterly SGA for Rein Therapeutics?
- What is Rein Therapeutics quarterly SGA year-on-year change?
- What is Rein Therapeutics TTM SGA?
- What is the all time high TTM SGA for Rein Therapeutics?
- What is Rein Therapeutics TTM SGA year-on-year change?
What is Rein Therapeutics annual SGA?
The current annual SGA of RNTX is $11.36 M
What is the all time high annual SGA for Rein Therapeutics?
Rein Therapeutics all-time high annual SGA is $13.45 M
What is Rein Therapeutics annual SGA year-on-year change?
Over the past year, RNTX annual SGA has changed by +$1.68 M (+17.32%)
What is Rein Therapeutics quarterly SGA?
The current quarterly SGA of RNTX is $2.35 M
What is the all time high quarterly SGA for Rein Therapeutics?
Rein Therapeutics all-time high quarterly SGA is $5.33 M
What is Rein Therapeutics quarterly SGA year-on-year change?
Over the past year, RNTX quarterly SGA has changed by -$1.39 M (-37.23%)
What is Rein Therapeutics TTM SGA?
The current TTM SGA of RNTX is -$1.20 B
What is the all time high TTM SGA for Rein Therapeutics?
Rein Therapeutics all-time high TTM SGA is -$114.34 M
What is Rein Therapeutics TTM SGA year-on-year change?
Over the past year, RNTX TTM SGA has changed by -$1.21 B (-9381.25%)